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Abstract 
Pulmonary arterial hypertension (PAH) is a progressive disease characterised by increased 
pulmonary vascular resistance and pulmonary artery remodelling as result of increased 
vascular tone and vascular cell proliferation, respectively. Eventually, this leads to right heart 
failure. Heritable PAH is caused by a mutation in the bone morphogenetic protein receptor-II 
(BMPR-II).  Female susceptibility to PAH has been known for some time and most recent 
figures show a female: male ratio of 4:1. Variations in the female sex hormone estrogen and 
estrogen metabolism modify FPAH risk and penetrance of the disease in BMPR-II mutation 
carriers is increased in females. Several lines of evidence point towards estrogen being 
pathogenic in the pulmonary circulation and thus increasing the risk of females developing 
PAH. Recent studies have also suggested that estrogen metabolism may be crucial in the 
development and progression of PAH with studies indicating that downstream metabolites 
such as 16α-hydroxyestrone are up-regulated in several forms of experimental pulmonary 
hypertension (PH) and can cause pulmonary artery smooth muscle cell proliferation and 
subsequent vascular remodelling. Conversely, other estrogen metabolites such as 2-
methoxyestradiol have been shown to be protective in the context of PAH. Estrogen may also 
upregulate the signalling pathways of other key mediators of PAH such as serotonin.  
Key words: Pulmonary arterial hypertension, vascular remodelling, sex hormones, estrogen, 
estrogen metabolites, serotonin. 
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Introduction 
Pulmonary arterial hypertension (PAH) is a debilitating disease characterised by an increase 
in pulmonary artery pressure and pulmonary vascular resistance. The World Health 
Organization (WHO) categorises PAH patients into five distinct functional classifications 
(Table 1) (Simonneau et al., 2013). 
Table 1: Clinical classification of pulmonary hypertension. 
Classification of Pulmonary Hypertension 
1. Pulmonary arterial hypertension 
1.1. Idiopathic PAH (IPAH) 
1.2. Heritable PAH (HPAH) 
1.4.1. BMPR-II 
1.4.2. ALK-1, ENG, SMAD9, CAV1, KCNK3 
1.4.3. Unknown 
1.3. Drug and toxin induced 
1.4. Associated with 
1.4.1. Connective tissue disease 
1.4.2. HIV infection 
1.4.3. Portal hypertension (PPHTN) 
1.4.4. Congenital heart disease 
1.4.5. Schistosomiasis 
1.4.6. Chronic haemolytic anaemia 
1.5. Persistent pulmonary hypertension of the newborn (PPHN) 
2. Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease (COPD) 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive patterns 
3.4 Sleep-related breathing behaviour 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitudes 
3.7 Developmental lung diseases 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Hematologic disorders: chronic haemolytic anaemia, myeloproliferative disorders, splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphagioleiomyomatosis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thryroid disorders 
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH 
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Occurrence of both idiopathic and familial PAH ranges from 6-10 cases per million in the 
population whereas the number of those patients developing PAH as a result of other illness 
is estimated to be much higher, although not reported (Barst, 2008). PAH is an incurable 
vasculopathy which affects the arteries of the pulmonary circulation and contributes to the 
morbidity and mortality of adult and paediatric patients with a wide range of lung and heart 
diseases. PAH is characterized by a progressive obstruction of distal pulmonary arteries and 
formation of plexiform lesions leading to elevated pulmonary vascular pressures and right 
heart failure. The pathogenesis of PAH is complex and involves numerous 
pathophysiological phenotypes including pulmonary artery endothelial cell (PAEC) 
dysfunction, pulmonary artery smooth muscle cell (PASMC) proliferation, apoptotic 
resistance, metabolic shift (Warburg effect), impaired angiogenesis, phenotypic transition and 
chronic inflammation (Tuder et al., 2013, Humbert et al., 2008, Rabinovitch, 2012).  
The non-specific nature of early PAH symptoms, including dizziness, syncope and fatigue 
often leads to delayed diagnosis, definitively by invasive right heart catheterisation (Montani 
et al., 2013). Consequently, patient’s exhibit more advanced pathophysiological features and 
therefore a lower quality of life. To date there is no known cure for PAH although there are a 
number of treatment options available targeting the main pathways involved in the 
pathogenesis of PAH.  
Endothelin receptor antagonists 
Endothelin 1 (ET- 1) is a 21 amino acid, vasoactive peptide. Under physiological conditions, 
ET-1 is produced in small amounts, mainly in endothelial cells, acting as an 
autocrine/paracrine mediator. The biological effects of ET-1 are transduced by two receptor 
subtypes, the ETA and ETB receptors. In the vasculature, the ETA receptor is mainly located 
on vascular smooth muscle cells, whilst ETB receptors are localized on both endothelial and 
vascular smooth muscle cells. Activation of ETA and ETB receptors on vascular smooth 
muscle results in vasoconstriction (Seo et al., 1994, McCulloch et al., 1996). The activation 
of endothelial ETB receptors located on the endothelium stimulates the release of nitric oxide 
(NO) and prostacyclin (Hirata et al., 1993) prevents apoptosis and plays a minor role in 
endothelial-dependent vasodilatation (Shichiri et al., 1997). The lungs are the major site for 
both clearance and production of circulating ET-1: up to 50% of circulating ET-1 is cleared 
through the ETB receptors (Dupuis et al., 1996).  
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In PAH an upregulation of the ET-1 system occurs.  ET-1 plasma levels are elevated and the 
increase is correlated with right atrial pressure, pulmonary artery oxygen saturation and 
pulmonary vascular resistance (Stewart et al., 1991).  ET-1 pre-cursor, prepro-ET-1, is also 
abundantly over-expressed in endothelial cells from patients with PAH (Giaid et al., 1993) 
and stimulates proliferation of PASMCs and vasoconstriction (Wort et al., 2001).  ET-1 
receptor antagonists, bosentan, macitentan and ambrisentan are currently approved for the 
treatment of PAH, preventing the aberrant activity of ET-1 observed in patients. Bosentan 
and macitentan are dual ETA and ETB receptor antagonist, whereas ambrisentan is a selective 
ETA receptor antagonist (Correale et al., 2013).  
Prostacyclin Analogues 
Prostacyclin is a member of the eicosanoid family of mediators, which include 
prostaglandins, thromboxanes and leukotrienes. It is a potent vasodilator and inhibitor of 
platelet aggregation.  Prostacyclin is synthesised from arachidonic acid by the actions of 
cyclo-oxygenase and prostacyclin synthase, primarily in endothelial cells. In PAH 
dysregulation of prostacyclin metabolic pathways occurs. A reduction in prostacyclin levels 
are observed, characterised by a decrease in urinary metabolites (Christman et al., 1992) and 
a decrease in prostacyclin synthase expression in the lungs of PAH patients (Tuder et al., 
1999). Several prostacyclin analogues including epoprostenol, iloprost and treprostinil are 
used clinically in the treatment of PAH (Galie et al., 2009). In addition to their vasodilator 
properties, prostacyclin analogues can also have inhibitory effects on PASMC proliferation 
and migration (Clapp et al., 2002). Hence, prostacyclin agonists and analogues are used to 
treat severe PAH. The most recent member of this drug class, selexipag, a selective 
prostacyclin receptor agonist, was approved by the Food and Drug Administration (FDA) for 
PAH in 2015 (Lau et al., 2017, Sharma, 2015). 
Phosphodiesterase – 5 (PDE-5) inhibitors  
The cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphates (cGMP) are important mediators of pulmonary vasodilation via activation of 
protein kinase A (PKA) and protein kinase G (PKG), respectively (Montani et al., 2014). NO 
is a well-established mediator involved in activation of the cGMP pathway. 
Phosphodiesterase’s (PDEs) catalyse the hydrolysis of cAMP and cGMP and promote 
vasodilation by increasing the concentration of both cyclic nucleotides intracellularly. PDE-5 
is cGMP selective and is highly expressed in the lung (MacLean et al., 1997). Inhibitors of 
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PDE5 promote vasodilation via cGMP and are effective in PAH management. PDE5 inhibitor 
drugs approved for the treatment of PAH include sildenafil, tadalafil and vardenafil (Rashid 
et al., 2017, Gao et al., 2017). 
Soluble guanylate cyclase stimulator 
Soluble guanylate cyclase (sGC) is the primary NO receptor. On binding to NO, sGC 
catalyses the synthesis of cGMP, which promotes vasodilation but also inhibits vascular 
smooth muscle cell proliferation, leukocyte recruitment, platelet aggregation and vascular 
remodelling. There is dysregulation of NO production, sGC activity and cGMP degradation 
in PAH (Stasch and Evgenov, 2013). This enzyme is a direct target to activate NO- sGC)- 
cGMP pathway and targeting of sGC stimulation by riociguat has consistently improved 
response to exercise following treatment in pulmonary hypertension patients (Lian et al., 
2017). This occurs via vasodilation within the pulmonary arterial bed thus improving 
hemodynamics and vascular tone. 
 
Sex as a risk factor in PAH 
In the 1950’s, Dresdale first documented an increased frequency of female PAH patients 
compared to men (Dresdale et al., 1951). The increased prevalence of PAH in females 
remains; evidenced by recent epidemiological studies highlighting that 70-80% of PAH 
patients are female (Badesch et al., 2010). This is in contrast to other demographics, which 
have changed over time i.e. age of diagnosis ranges from 50-65 years in contemporary 
registries compared to 36 years previously reported (Hoeper and Gibbs, 2014). As the age of 
diagnosis has increased, patients are presenting with more co-morbidities, and are therefore 
more difficult to manage clinically. However, reasons underlying the imbalanced female to 
male ratio regarding disease prevalence remain obscure. Conversely, male PAH patients 
exhibit poorer survival than female patients (Jacobs et al., 2014), leading to investigation of 
the phenomenon known as the ‘sex paradox’ in pulmonary hypertension. Recent studies 
suggest that males have poorer adaptive remodeling of the right ventricle  (RV) in response to 
increased afterload - this may explains sex differences in survival in PAH (Jacobs et al., 
2014). Such paradoxical observations suggest a role for complex sex hormone signaling and 
processing pathways in the development and progression of PAH (Foderaro and Ventetuolo, 
2016). This sex paradox also seems to be dependent on the age of PAH patients with the age 
of onset being earlier in women than men, perhaps due to altered estrogen production at 
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menopause. The influence of sex hormones in women presenting with PAH is further 
suggested by the onset of PAH during pregnancy and/or post-partum period (Terek et al., 
2013). While treatment guidelines now suggest that female PAH patients do not take 
estrogen-based contraceptives (Hemnes et al., 2015), current PAH therapies do not take sex 
bias into account despite recent studies having shown sex differences in treatment response 
(Gabler et al., 2012, Shapiro et al., 2012). For example, Gabler and colleagues reported that 
ET-1 receptor antagonists had greater efficacy in females than males (Gabler et al., 2012). A 
more recent study found increased likelihood of response to PDE5 inhibitor, tadalafil in the 
treatment of PAH, in men compared with women (Mathai et al., 2015). Sex-specific 
heterogeneity in treatment response may reflect differences in PAH pathobiology, and afford 
the opportunity to inform individual treatment decisions and provide the basis for exploring 
potential differences in mechanisms of disease between sexes. 
 
Sex differences in the BMPR-II signalling pathway in pulmonary 
hypertension 
Bone morphogenic protein (BMP) receptor type II (BMPR-II) is a serine/threonine 
transmembrane type II receptor kinase, belonging to the transforming growth factor (TGF)-β 
super family. BMPR-II is involved in processes such as development, embryogenesis and 
adult tissue homeostasis. BMP ligands cause the formation of a heterodimer between BMPR-
II and a type I receptor. Following heterodimer formation and the phosphorylation of the type 
I receptor there is phosphorylation of Smad 1/5/9 proteins which in turn leads to the 
upregulation of expression of nuclear Inhibitor of Differentiation 1 and 3 (Id1/Id3), both 
Id1/Id3 act to repress proliferation. The proliferation, migration and apoptosis of both 
endothelial cells and smooth muscle cells within the vasculature can be influenced by BMP 
signalling (Garcia de Vinuesa et al., 2016). Mutations in the gene encoding for BMPR-II is 
the most well established risk factor for heritable PAH. Over 300 different mutations sites 
within the BMPR-II gene have been identified in PAH patients and are associated with PAH 
development and progression. Approximately 75% of familial PAH cases and 20% of 
idiopathic PAH cases are associated with a loss-of-function mutation in this gene (Machado 
et al., 2009). The penetrance of BMPR-II mutations are particularly low, only approximately 
20% of male carriers develop PAH whilst approximately 45% of female carriers develop the 
disease (Newman et al., 2004). Therefore, other genetic and environmental risk factors must 
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exist. Alternative splicing of BMPR2 is thought to play a role in the penetrance of the 
disease. BMPR-II can be alternatively spliced producing 2 different isoforms – the full 
transcript and one lacking exon 12. Exon 12 is the largest exon within BMPR-II and encodes 
a cytoplasmic domain (Machado et al., 2006). The ratio of the isoform-B to isoform-A is 
increased in PAH patients when compared to unaffected BMPR-II mutation carriers. 
Therefore is has been suggested that expression of isoform B is involved in the penetrance of 
the disease (Cogan et al., 2012). 
A reduction in BMPR-II signalling and therefore a reduction in the anti-proliferative Id1/3 
leads to increased proliferation of the PASMCs (Morrell et al., 2009) and subsequent 
pathological remodelling of the pulmonary vasculature. It has been demonstrated that PAH 
patients harbouring a BMPR-II mutation develop the disease at an earlier age and have worse 
hemodynamic profiles at the time of diagnosis than those patients without a BMPR-II 
mutation. As a result, BMPR-II mutation carriers have an increased mortality (Evans et al., 
2016).  
It is well established that a greater number of females develop PAH. There are sex specific 
differences in the expression and activity of BMPR-II, even under basal conditions, which 
could contribute to the greater number of females within the PAH patient population. Female 
PASMCs obtained from non-PAH subjects have been shown to have reduced expression of 
BMPR-II at both a gene and protein level when compared to male PASMCs obtained from 
non-PAH subjects (Mair et al., 2015). Furthermore, the downstream factors in the BMPR-II 
signaling pathway, Smad 1 and Id1/3, were also down regulated in female PASMCs. This 
suggests that females could be pre-disposed to PAH because they have basally lower levels of 
BMPR-II. Interestingly, when male non-PAH PASMCs were stimulated with estrogen, no 
changes were observed in the expression of BMPR-II and Smad 1, yet there was a reduction 
in mRNA and protein levels of the Id genes (Mair et al., 2015). Therefore, estrogen could be 
responsible for driving the suppression of the BMPR-II pathway and the predisposition of 
females to PAH. Other sex specific differences in BMPR-II expression have been highlighted 
in PAH patients. BMPR-II gene expression in lymphocytes was approximately 20% lower in 
female patients than in male patients (Austin et al., 2012). When comparing whole lung 
BMPR-II expression in male and female mice, BMPR-II gene expression was lower in the 
female, compared to male mouse. The same study also highlighted an estrogen response 
element (ERE) in the BMPR-II promotor. This ERE was found to be a highly conserved 
functional binding site for estrogen receptor alpha (ERα) (Austin et al., 2012). Therefore, it is 
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suggested that estrogen is able to reduce expression of BMPR-II through the direct binding of 
ERα to the BMPR-II promoter. In addition, we have demonstrated decreased BMPR-II 
signalling in lungs from the sugen-hypoxic rat model of pulmonary hypertension (Mair et al., 
2014b). Inhibition of estrogen synthesis with an aromatase inhibitor reversed the 
experimental pulmonary hypertension in the female rats and restored the deficient BMPR-II 
signalling (Mair et al., 2014b), suggesting that endogenous estrogen can supress BMPR-II 
signalling in vivo. This strengthens the hypothesis that estrogen can cause sex specific 
differences in BMPR-II expression, which ultimately results in the predisposition of females 
to PAH. Despite dysfunctional BMPR-II signalling being well characterised in the lung, the 
downstream effects in the RV are not well understood. A recent clinical study suggested 
BMPR-II mutation carriers have poorer RV function despite similar afterload and cardiac 
adaptation in mutation carrier and non-carrier groups (van der Bruggen et al., 2016). This 
study suggests that BMPR-II signalling can influence RV dysfunction in PAH. Currently, 
little is known regarding sex specific differences in BMPR-II expression in the RV and the 
potential effects this might have on RV function in PAH. 
 
The influence of sex hormones in pulmonary hypertension 
A recent comprehensive study by Ventetuolo and colleagues characterised the relationship of 
sex and hemodynamics in PAH (Ventetuolo et al., 2014). Ventetuolo et al, also recently 
demonstrated robust clinical data outlining significantly increased plasma estrogen levels in 
male idiopathic PAH patient’s vs control subjects (Ventetuolo et al., 2016a). Differential 
effects of estrogen on the pulmonary circulation and RV and/or differential metabolism of 
estrogen to mitogenic or anti-proliferative metabolites may well explain the differences 
observed in outcomes of animal models as well as the notable sex difference in the incidence 
of the disease.  
One hypothesis that may explain the female susceptibility in PAH is that the female hormone 
estrogen is pathogenic in the pulmonary circulation. The estrogen pathway is known to be 
affected in diseases such as systemic lupus erythematosus and breast cancer, both of which 
have a higher female prevalence (Ohta et al., 2013). Progesterone, testosterone, DHEA, as 
well as estrogen and metabolites have been shown to affect pulmonary vascular tone and cell 
proliferation (Lahm et al., 2014). Male rodents with hypoxia- or monocrotaline-induced PH 
develop more severe experimental PH than females whilst there is no sex-bias in 
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Sugen/hypoxic rodent models (Umar et al., 2012, Mair et al., 2014a). In experimental models 
of PH (hypoxia-induced and monocrotaline-induced) where male animals are dosed with 
exogenous estrogen, this exerts protective, vasodilatory and anti-proliferative effects (Lahm 
et al., 2012). Exogenously administered estrogen can improve RV function in the 
Sugen/hypoxic model of PH by stimulating RV contractility and protecting against 
pulmonary vascular remodelling (Liu et al., 2014). However, inhibiting endogenous estrogen 
with an aromatase inhibitor reverses sugen/hypoxic-induced PH in females and in BMPR2 
mutant mice without affecting RV function implying that local endogenous estrogens are 
protective (Mair et al., 2014b, Dean et al., 2016, Chen et al., 2017). However, eliminating 
endogenous circulating estrogen via ovariectomy also abolishes the PH phenotype in female-
susceptible transgenic mice including serotonin transporter (SERT) overexpressing (SERT+) 
mice (White et al., 2011), Smad1+/- mice (Mair et al., 2015) and dexfenfluramine-treated mice 
(Dempsie et al., 2013). 
 
The role of sex hormones and sex hormone metabolites in pulmonary arterial 
hypertension 
 
Estrogen Biosynthesis and Metabolism 
The female sex hormones are steroid hormones that comprise both estrogens and 
progesterones. Steroid hormones have multi-factorial functions throughout the body and are 
synthesized from cholesterol in the gonads, adrenal glands and placenta and to a lesser extent 
in the adipose tissue, liver and skin (Knowlton, 2012). Estrogens are the primary female sex 
hormone involved in development and maintenance of the female reproductive system. 
Evidence also exists for a significant role for estrogens in other systems including the 
cardiovascular system (Knowlton, 2012). Such that, synthesis of estrogen can also take place 
in liver and adipose tissue and the reported expression of estrogen-synthesising enzymes in 
vascular smooth muscle cells and endothelial cells (Tofovic, 2010) implicates the importance 
of ‘local’ estrogen synthesis and autocrine/paracrine effects out with the reproductive organs.  
Estrogens exist as three major naturally occurring isoforms: estrone, estrogen and estriol. 
Estrogen is the predominant circulating hormone in pre-menopausal women, whilst estrone is 
important during the menopause and estriol during pregnancy. In the follicular phase, 
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circulating concentrations of estrogen are about ~0.4nM and during ovulation these levels 
rise to ~2.2nM. After menopause, estrogen levels are reduced up to 20-fold (Mendelsohn and 
Karas, 1999). The biosynthesis of estrogen is initiated by the synthesis of androstenedione 
from the precursor cholesterol. Androstenedione provides an intermediate stage in 
metabolism from which estrogen can be synthesised by cytochrome P450 enzyme (CYP) 
19A1 (aromatase) which converts androstenedione to estrone, which in turn is converted to 
estrogen by 17β hydroxysteroid dehydrogenase 1 (17βHSD1). Alternatively, reduction of 
androstenedione to testosterone, can occur via 17β hydroxysteroid dehydrogenase 2 
(17βHSD2), followed by aromatisation of testosterone to estrogen.  
As a predominantly female hormone, estrogen is assumed detrimental in generating the high 
prevalence of female PAH patients. For example, polymorphisms in aromatase, the estrogen 
synthesising enzyme, and the gene for ERα (Esr1), are associated with elevated estrogen 
levels in the lungs of female patients and predispose to porto-pulmonary hypertension 
(Roberts et al., 2009, White et al., 2012). In agreement, heightened exposure to exogenous 
estrogen through both use of oral contraceptives and hormone replacement therapy is 
associated with PAH (MASI, 1976). On the contrary, there is evidence to suggest hormone 
replacement therapy can prevent the development of PH in patients with systemic sclerosis 
(Beretta et al., 2006).  
 
Aromatase 
Certain tissues can modulate their own estrogenic milieu by the local conversion of 
testosterone or androstenedione to estrogen and estrone, by the activity of aromatase which is 
expressed within the pulmonary arteries (Harada et al., 1999, Mair et al., 2014b). Circulating 
aromatase precursors act as a reservoir for the synthesis of estrogens within extra-gonadal 
sites, namely; androstenedione, dehydroepiandrosterone (DHEA) and DHEA-sulphate 
(DHEA-S) (Simpson, 2003). Locally synthesised estrogens can act in a paracrine or autocrine 
fashion creating a potentially potent estrogenic milieu that may be superior to the effects of 
circulating levels. The aromatase gene is present in gonadal and extra-gonadal tissues with its 
site-specific transcription being driven by different signaling pathways at alternative sites in 
the promoter region.  
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Expression of aromatase has also been defined within lung tissue giving rise to the presence 
of a local pulmonary vasculature estrogenic microenvironment. The aromatase inhibitor 
anastrozole has shown remarkable therapeutic potential in the Sugen5416-hypoxic rat model 
and hypoxic rat model where it successfully reversed the PH phenotype in female rats and 
this correlated with reduced plasma estrogen levels and restored BMPR-II signaling (Tofovic 
and Jackson, 2013, Mair et al., 2014b). Inhibition of aromatase, by anastrozole is now widely 
recognised for use in estrogen sensitive breast cancer (Forbes et al., 2008). The therapeutic 
potential in PAH of anastrozole, has very recently been shown to be safe and effective in a 
small proof of concept study (Kawut et al., 2016), where anastrozole significantly reduced 
estrogen levels and improved 6-minute walk distance (6MWD). These results are promising 
and suggest that longer and larger Phase II trials of anastrozole are warranted. 
 
Oxidative Metabolism of Estrogens: Cytochrome P450 Enzymes 
Estrogen can be rapidly metabolised by oxidation. Oxidative metabolism occurs primarily in 
the liver producing non-Estrogenic metabolites ready for elimination from the body. Estrogen 
and estrone are in equilibrium with 17βHSD1, and oxidation/reduction occurs at the carbon 
(C)-17 position and favours formation of estrone. Further metabolism of estrogen occurs, for 
example, at the C16, C4 and C2 positions producing biologically active metabolites, 
including 16α-hydroxyestrone (16αOHE1). CYPs contain an iron (Fe3+) docking site for 
oxygen, which in the presence of NADPH is reduced (Fe2+). CYP enzymes are critically 
involved in xenobiotic metabolism, as well as metabolism of eicosanoids, steroids and 
cholesterol synthesis, amongst others. Metabolism by the activity of CYP enzymes has a 
genotoxic capacity via the generation of reactive oxygen intermediates that can interact with 
nucleic acids and proteins and initiate tumorigenesis (Nebert and Dalton, 2006). Specifically, 
CYP1A1, CYP1A2, CYP1B1, and CYP3A4 appear critical in the formation of 2- and 4- 
hydroxy-derivatives of estrogen. The 2-hydroxylation pathway is the major metabolic 
pathway in the liver whereas 4-hydroxylation constitutes a relatively minor pathway. The 2-
and 4-hydroxy-derivatives are then further converted/deactivated to 2- and 4-methoxy 
metabolites by the catechol-O-methyltransferase (COMT), reducing the capacity to redox 
cycle/generate quinones and semiquinones. In a regulatory feedback mechanism, estrogen 
can promote its own breakdown by driving the transcription of the human CYP1B1 gene via 
an ERE in the promoter region (Tsuchiya et al., 2005).  
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CYP1B1 in PH 
There is evidence that CYP1B1 may play an important role in the pathogenesis of PAH. 
CYP1B1 is highly expressed in pulmonary arteries from patients with PAH and the CYP1B1 
inhibitor, 2,3’,4, 5’-tetramethoxystilbene (TMS) can reverse PH in sugen/hypoxic and 
hypoxic models of PH (White et al., 2012b). In addition it increases survival in the 
monocrotaline rat model of pulmonary hypertension (Johansen et al., 2016). TMS also 
abolished estrogen-induced proliferation in hPASMCs from controls and patients (White et 
al., 2012a). Genetic polymorphisms in CYP1B1 and the estrogen metabolites produced by 
this enzyme have also been identified as factors influencing the penetrance of the disease in 
individuals with BMPR-II mutations (Austin et al., 2009). Indeed a CYP1B1 SNP in tight 
linkage disequilibrium with SNPs associated with pulmonary hypertension has been 
identified, suggesting these pathways may underpin sexual dimorphism in RV failure 
(Ventetuolo et al., 2016b). 
Serotonin and dexfenfluramine can also increase the expression of CYP1B1 in PASMCs 
(Johansen et al., 2016, White et al., 2011, Dempsie et al., 2013). Indeed, TMS and/or 
CYP1B1 deletion in mice reverses the development of PH in SERT+ mice or 
dexfenfluramine-treated mice (Dempsie et al., 2013, Johansen et al., 2016). Dexfenfluramine 
up-regulated expression of CYP1B1 in PASMCs from PAH patients and dexfenfluramine-
mediated proliferation these cells was ablated by the CYP1B1 inhibitor, TMS. Estrogen also 
increased expression of CYP1B1 in PAH-derived PASMCs (Dempsie et al., 2013). 
The enzyme CYP1B1 is involved in both the metabolism of estrogen, and arachidonic acid. 
In the lungs, epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic acids (HETEs) 
have inflammatory and mitogenic effects. 20-HETEs increase NADPH oxidase (Nox)-
derived reactive oxygen species (ROS) production in bovine PAECs (Medhora et al., 2008, 
Choudhary et al., 2004) and are implicated in the development of hypoxic PH (Zhu and Ran, 
2012). Notably, EETs have opposite effects in the systemic circulation, which may explain 
the plausible divergent effects of estrogen in the systemic versus the pulmonary circulation 
(Zhu and Ran, 2012). 
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16α-hydroxyestrone in the development of PH 
16αOHE1 has been shown to be a biologically active and significantly more estrogenic than 
estrogen at the classical estrogen receptors ERα and ERβ (Mueck et al., 2002, Austin et al., 
2012). Urinary levels 16αOHE1 were elevated in a hypoxia-induced PH model and, when 
administered to mice, 16αOHE1 caused a significant increase in RV hypertrophy (RVH), 
pulmonary artery remodeling and RV systolic pressure (RVSP) (White et al., 2012). 
16αOHE1 also induced proliferation in PASMCs confirming this pro-proliferative phenotype 
in the human setting (White et al., 2012). Indeed, an increase in plasma 16αOHE1 levels have 
been demonstrated in 4,40 -Methylenedianiline (DAPM)- induced PH in rats providing 
further evidence for a role for 16αOHE1 in the development of experimental PH (Carroll-
Turpin et al., 2015). Austin et al., (2009) established a link between altered estrogen 
metabolism and penetrance in heritable PAH. Here, a decreased ratio of 2-
hydroxyestradiol/16αOHE1 was observed in affected BMPR-II mutation carriers vs 
unaffected BMPR-II mutation carriers, thus suggesting a shift to the pro-proliferative 
phenotype observed in heritable PAH (Austin et al., 2009). The molecular mechanism for 
16αOHE1-induced proliferation appears to be complex and is at least in part, mediated by 
ROS. 16αOHE1 induces superoxide and hydrogen peroxide production and downregulates 
the protective effects of Nuclear factor erythroid-derived like factor 2 (Nrf-2) through Nox1 
and ERα (Hood et al., 2016). Together, these studies further emphasize the potential role 
16αOHE1 may play in the development of PAH.  
 
2-methoxyestradiol as an anti-proliferative metabolite 
There is an increasing body of evidence suggesting that some estrogen metabolites can be 
protective in the setting of PAH. The 2-methoxyestrogens are perhaps the best example of the 
estrogen metabolites known to have beneficial effects in the pulmonary vasculature. Indeed, 
2-methoxyestradiol (2ME2) has been studied extensively in the context of many cancers and 
much research has centred around the metabolites’ anti-proliferative and potentially pro-
apoptotic nature within this setting. 2ME2 is metabolized from its precursor metabolite 2-
hydroxyestradiol (2OHE2) by the enzyme, COMT. 2ME2 is also readily converted to its less 
biologically active form 2-methoxyestrone (2ME1) by 17βHSD2 (Tofovic, 2010).  
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It is only within the last decade or so that several studies have outlined the potential 
beneficial effects of 2ME2 in the context of pulmonary hypertension. Tofovic et al., have 
demonstrated that 2ME2 reversed indices such as RVH, RVSP, pulmonary artery remodeling 
and increased survival in the monocrotaline and bleomycin models of experimental 
pulmonary hypertension (Tofovic et al., 2005, Tofovic et al., 2010a). 2ME2 has also been 
shown to reduce human PASMC and human lung fibroblast proliferation in a concentration 
dependent manner (Tofovic et al., 2009b) thus demonstrating that 2ME2 has beneficial 
effects in PASMC remodeling as well as pulmonary fibrosis and associated adventitial 
remodeling. Indeed, further pre-clinical studies have shown that, in the monocrotaline-
induced PH model, combination therapy of 2ME2 and sildenafil significantly reduced 
pulmonary artery remodeling and inflammatory responses as well as increasing survival 
(Tofovic et al., 2010b). 2-ethoxyestradiol, a synthetic analogue of 2ME2, also attenuates 
experimental PH and is 10-times more potent than 2ME2 both in-vitro and in-vivo (Tofovic 
et al., 2008). The exact mechanism to which 2ME2 exerts its potent anti-proliferative effect 
are unclear. However, there is evidence to suggest that 2ME2 reduces endothelial cell 
production of the potent mitogen ET-1 through alterations in mitogen activated protein kinase 
(MAPK) activity, this reduction in ET-1 was also demonstrated to be ERα and ERβ 
independent (Dubey et al., 2001). Further work is required to elucidate the exact mechanism 
of action of 2ME2 and whether it may well be useful in a clinical setting. 
 
Other potential protective estrogen metabolites 
To date there is limited data demonstrating other beneficial estrogen metabolites; however, 
some studies have shown that the hydroxy metabolite 2OHE2 can reverse monocrotaline-
induced PH in male rats through a reduction in RVH and pulmonary artery remodeling 
(Tofovic et al., 2005). 2OHE2 has anti-proliferative effects in rat cardiac fibroblasts and it 
has been demonstrated that the anti-proliferative effect of 2OHE2 is mediated through 
conversion to 2ME2 by COMT. Furthermore, 2ME2 and 2OHE2’s anti-proliferative effects 
are independent of ERα and ERβ (Dubey et al., 2001). 4-hydroxyestradiol (4OHE2) is anti-
proliferative in male human PASMCs (Mair et al., 2015). Interestingly, 4OHE2 is pro-
proliferative in the breast adenocarcinoma cell line, MCF-7, suggesting possible tissue and 
cellular specific effects (Seeger et al., 2006). 
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Other sex hormones of interest 
Although estrogen and its metabolites have been the focus of research, other sex hormones 
are biologically active in the pulmonary vasculature. For example, the female steroid 
hormone progesterone has been shown to be vasodilatory in systemic and pulmonary arteries 
mediated through an endothelium dependent NO induced induction of cGMP as well as 
inhibition of voltage and receptor operated calcium channels (Glusa et al., 1997, Li et al., 
2001). Furthermore, progesterone is anti-proliferative in aortic smooth muscle cells (Lee et 
al., 1997); however, whether it is also anti-proliferative in the pulmonary vasculature is 
unknown. Pre-clinically, progesterone attenuates monocrotaline-induced pulmonary 
hypertension in rats by reducing RVSP, RVH and vascular remodeling whilst also 
significantly increasing survival (Tofovic et al., 2009a). However, the effects of progesterone 
on the pulmonary vasculature in the clinical setting are as yet unknown and an avenue open 
to future investigation.  
The male sex hormone testosterone has also been postulated to be beneficial in the setting of 
pulmonary hypertension, not only because fewer males are afflicted with the disease but also 
because it has been shown to be a potent vasodilator in isolated pulmonary arteries of both 
rats (English et al., 2001) and humans (Smith et al., 2008). However, in human pulmonary 
arteries, the vasodilatory property of testosterone is much more efficacious in males (Rowell 
et al., 2009). Indeed, Jones et al., have demonstrated that testosterone is likely to exert this 
vasodilatory effect via calcium antagonistic effects on voltage gated calcium channels 
independent of the androgen receptor (Jones et al., 2002). However, in the cardiac setting 
testosterone has been shown to promote maladaptive RV remodeling and fibrosis suggesting 
a detrimental effect on overall RV function in the context of increased afterload (Hemnes et 
al., 2012). This observation is in line with current clinical data where males with PAH have 
worse clinical outcomes than females (Benza et al., 2010, Humbert et al., 2010). There is 
little clinical data regarding testosterone treatment in PAH; however, there were no 
differences observed in plasma testosterone levels between male healthy and PAH patients in 
a recent study by Ventetuolo and colleagues (Ventetuolo et al., 2016a). 
DHEA, the precursor steroid hormone to testosterone, can inhibit hypoxia-induced 
vasoconstriction of the pulmonary arteries via opening of Ca2+-activated large conductance 
potassium channels (BKCa) (Farrukh et al., 1998). In vivo, DHEA also prevents and reverses 
hypoxia-induced PH in rats by increasing the expression and functionality of BKCa channels 
to increase vasodilation of the pulmonary arteries (Bonnet et al., 2003). Indeed, other groups 
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have demonstrated the beneficial effects of DHEA on the pulmonary vasculature (Oka et al., 
2007) as well as its ability to improve cardiac endpoints such as increasing tricuspid annular 
plane systolic excursion (TAPSE), RV internal diameter during diastole and cardiac index 
(CI) ultimately increasing right ventricular function (Alzoubi et al., 2013). Interestingly, 
DHEA has also been shown to inhibit Src/STAT3 activation and upregulate BMPR-II 
expression in PASMCs isolated from human PAH patients further outlining its protective 
effects in the pulmonary vasculature (Paulin et al., 2011). Preliminary clinical studies 
involving DHEA have been promising, for example in a small clinical trial oral DHEA 
treatment improved the 6MWD and pulmonary hemodynamics in chronic obstructive 
pulmonary disease (COPD)-induced PH (Dumas de La Roque et al., 2012). Furthermore, 
lower plasma DHEA-S levels have been found in male PAH patients, further suggesting a 
potential protective role for the hormone in the pulmonary vasculature (Ventetuolo et al., 
2016a). 
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Estrogen receptors and sex-specific differences 
It has become apparent that estrogen receptors impact a multitude of biological functions 
including inflammatory response, cardiovascular function (El Khoudary, 2017) and bone 
homeostasis (Bado et al., 2017). The majority of estrogenic activity is via canonical 
estrogenic signalling. Upon high affinity binding with estrogen these nuclear receptors act as 
transcription factors regulating gene activity (Lee et al., 2012). Estrogen signaling targets 
three main classes of estrogen receptors: the nuclear ERα, ERβ and a transmembrane G 
protein-coupled estrogen receptor (GPER). All are located in various target organs mediating 
genomic and non-genomic estrogen signaling. Significantly, in PAH these receptors localise 
to the PASMCs that may account for estrogen-dependant proliferation and remodelling 
(Wright et al., 2015b). Structurally ERα and ERβ both display sequence homology 
comprising of five distinct domains, two activation domains within the n-terminal and ligand-
binding domains regulate the transcriptional activity of ER (Kumar et al., 2011). Due to 
alternative splicing, several isoforms of each also exist with at least three ERα and five ERβ 
isoforms discovered to date.  
ERα is highly expressed in female hPASMCs from PAH patients and mediates estrogen-
induced proliferation via MAPK and Akt signaling (Wright et al., 2015). High levels of ERα 
leads to human PASMC proliferation and remodelling, characteristic in PAH, through 
various canonical signalling pathways (Awad et al., 2016). The second receptor ERβ may 
play a more beneficial role in protection against PAH modulating angiogenesis through the 
production of various angiogenic factors such as vascular endothelial growth factor (VEGF) 
and NO (de Jesus Perez, 2011) upon estrogen treatment. Interestingly use of an ERβ agonist 
induced reversal of PAH symptoms with a prevention of the savour by application of ERβ 
antagonists. Therefore, postulations suggest that targeting ERβ in future therapeutics 
strategies may lead to the development of PAH treatments (Umar et al., 2011). 
The third class and more recently discovered transmembrane GPER, binds estrogen causing 
rapid non-genomic effects (Wright et al., 2015). In vascular physiology, GPER initiates rapid 
non-genomic effects via opening of ion channels and activation of various signaling enzymes. 
Relations between GPER and high blood pressure in aging males and females however the 
majority of studies to date suggests a beneficial role in the pulmonary vasculature and RV 
(Lahm et al., 2014). The potential beneficial effects of GPER include anti-fibrotic effects, 
enhanced cardiac contractibility and most notably the ability to mediate the protective effects 
of estrogen. Whilst GPER agonists do not exert a proliferative effect on hPASMCs, they have 
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been shown to reduce RV overload in PH rats and so GPER’s may play a role in the 
development of experimental PH (Wright et al., 2015, Alencar et al., 2017).   
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Serotonin and sex differences in pulmonary hypertension  
5-hydroxytryptamine (5-HT), or “serotonin”, was chemically identified by Rapport et al 
(1948) as one of the major vasoconstricting substances in defibrinated blood, originating 
from platelets (Rapport et al., 1948). Serotonin was subsequently found to also act as a major 
neurotransmitter, being involved in a variety of processes carried out by the central nervous 
system, as well as regulating several functions in the periphery. The biosynthesis pathway 
converts dietary tryptophan to 5-hydroxytryptophan by the action of the enzyme tryptophan 
hydroxylase (TPH). This process is the rate-limiting step in the generation of serotonin. Two 
isoforms of TPH exist; TPH1 is responsible for synthesis of serotonin in the periphery while, 
TPH2 is expressed abundantly in the brain (Nakamura and Hasegawa, 2007). 5-
hydroxytryptophan is then decarboxylated by a ubiquitous amino-acid decarboxylase, 
resulting in the formation of serotonin. The physiological effects of serotonin are then 
mediated by 14 different 5-HT receptor subtypes. These receptors are divided into 7 distinct 
classes (5-HT1 – 5-HT7), mainly on the basis of their structural and functional characteristics. 
Serotonin is also a substrate for SERT, which actively uptakes serotonin into cells. In the 
lungs, serotonin is locally released from pulmonary neuroendocrine cells and neuroepithelial 
cell bodies distributed throughout the airways. Synthesis of serotonin can also occur in 
PAECs. Furthermore, the lungs play an important role in the removal of serotonin from the 
circulation, with as much as 95% being taken up or inactivated. Under normal circumstances, 
pulmonary tissue is exposed to low levels of serotonin as most serotonin is stored in platelets, 
thus removing it from the circulation (Wiersma and Roth, 1980, Thomas and Vane, 1967, 
Gaddum et al., 1953). However, under hypoxic conditions (Johnson and Georgieff, 1989), 
and during situations involving mechanical strain (Pan et al., 2006), large amounts of 
serotonin are secreted. In the pulmonary circulation, serotonin promotes PASMC 
proliferation, vasoconstriction and thrombosis, processes involved in the development of 
PAH. 
 
An increased incidence of PH due to use of the anorexigenic drugs aminorex and 
dexfenfluramine; SERT substrates and indirect serotonergic agonists; stimulated interest in 
the role of serotonin in PAH, leading to the ‘serotonin hypothesis of PAH’. Aminorex 
increases plasma levels of serotonin by inducing its release from platelets and attenuating its 
breakdown (Zheng et al., 1997, Fishman, 1999). Dexfenfluramine also increases levels of 
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circulating serotonin and interacts with SERT, stimulating the release of serotonin from 
platelets and inhibit its reuptake (Buczko et al., 1975, Fristrom et al., 1977). 
A body of evidence now exists further implicating serotonin and the development of PAH. 
For instance some cohorts of patients with PAH have elevated plasma levels of serotonin, in 
addition to a decrease in the levels of serotonin stored in platelets due to platelet pool storage 
disease (Herve et al., 1995). Furthermore, in PAECs from PAH patients, increased TPH1 
expression and serotonin synthesis has been observed and this is thought to contribute to 
increased PASMC proliferation (Eddahibi et al., 2006). Knockdown of the TPH1 gene also 
has beneficial effects in animal models of PH (Morecroft et al., 2007, Morecroft et al., 2012). 
Indeed, synthesis of serotonin has also been associated with the development of the 
Sugen5416/hypoxic model of PH. Inhibition of the VEGF receptor by Sugen5416 combined 
with hypoxia generates a preclinical model of PH that recapitulates human PAH more closely 
than previously characterized models (Gomez-Arroyo et al., 2012). This model is associated 
with increased expression of TPH1, the rate-limiting enzyme in serotonin synthesis (Ciuclan 
et al., 2011, Ciuclan et al., 2013). 
 
5-HT receptors, in particular the 5-HT1B receptor and SERT contribute to the actions of 
serotonin in PH. Serotonin is a potent vasoconstrictor and in human pulmonary arteries 
mediates its effects via the 5-HT1B receptor (Morecroft et al., 1999), which is also over-
expressed in PASMCs from female PAH patients (Wallace et al., 2015) and in the pulmonary 
circulation of larger experimental models of PH such as pigs (Rondelet et al., 2003). In 
addition to the role of 5-HT1B receptors in vasoconstriction, they also play a role in 
mediating cellular proliferation and vascular remodeling. Several cellular studies have 
demonstrated the mitogenic effects of serotonin on pulmonary artery endothelial, smooth 
muscle and fibroblast cells.  Moreover, in experimental models of PH genetic ablation and 
pharmacological inhibition of the 5-HT1B receptor attenuate PH and inhibit pulmonary 
vascular remodeling (Hood et al., 2017, Keegan et al., 2001). SERT is also critical in 
mediating the mitogenic effects of serotonin in the pulmonary circulation. Augmented 
proliferative capabilities of PASMCs from patients with PAH have been associated with 
increased expression levels of SERT (Eddahibi et al., 2001, Marcos et al., 2004). The 
enhanced proliferation of these cells to 5-HT or serum can be abolished by SERT inhibitors 
such as citalopram and fluoxetine (Marcos et al., 2004). In PAH patients, SERT expression is 
also located mainly in the medial layer of remodeled vessels (Eddahibi et al., 2001). Hypoxia 
causes increased SERT expression and activity, augmenting mitogenic responses in PASMCs 
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(Eddahibi et al., 1999). Serotonin-induced proliferation requires SERT-dependent generation 
of ROS, activation of the extra-cellular regulated kinase (ERK) pathway and the induction of 
the transcriptional factor GATA-4. Activation of the Rho kinase pathway by internalised 
serotonin may also play a role in SERT-mediated proliferation (Lawrie et al., 2005, Liu et al., 
2004, Suzuki et al., 2003). Both the serotonin receptors and SERT can also interact in a co-
operative fashion to mediate serotonin-induced contraction and proliferation of PASMCs 
(Morecroft et al., 2005, Lawrie et al., 2005, Liu et al., 2004). Through its actions via SERT 
and its receptors, serotonin plays a role in the development of PAH, contributing to both 
vasoconstriction and vascular remodeling. Serotonin can also influence other pathways 
associated with PH and may act as a “second hit” as exogenous administration of serotonin 
uncovers a PH phenotype in BMPR-II +/-mice (Long et al., 2006). 
 
Models of PH have now been characterised that mimic the female susceptibility to PH 
observed in humans. These models all involve serotonin-dependent mechanisms and include: 
SERT+ mice, mice overexpressing the calcium-binding protein S100A4/mts1 (that function 
downstream of serotonin) and mice dosed with the indirect serotonergic agonist 
dexfenfluramine (Dempsie et al., 2013, Dempsie et al., 2011, White et al., 2011). In each of 
these models a PH phenotype is only observed in female animals and is estrogen-dependent. 
For instance, removal of female sex hormones by ovariectomy reverses the PH phenotype in 
SERT+ mice and the phenotype can be reinstated by replacing estrogen in these animals. 
Serotonin mechanisms may also be important in regulating estrogen metabolism as SERT 
overexpression and dexfenfluramine can increase CYP1B1 expression (Dempsie et al., 2013, 
Johansen et al., 2016). Furthermore, estrogen has been shown to increase the expression of 
TPH1, SERT, and the 5-HT1B receptor in human PASMCs (Dempsie et al., 2013, White et 
al., 2011). Indeed, increased 5-HT1B receptor expression in human PASMCs for female PH 
patients may be the consequence of an estrogen-induced decreases in miRNA-96 expression 
and contribute to the development of PH in females (Wallace et al., 2015). 
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Concluding statement  
Female sex is now recognised as a significant risk factor in the development of PAH. An 
increasing body of evidence now suggests that estrogen and some of its metabolites may play 
a role in the pathogenesis of PAH as well as experimental PH (Figure 1). Interactions of 
estrogen with serotonin and other key pathways may contribute to the development of PH. 
Furthermore, initial pre-clinical studies suggest that other estrogen metabolites such as 2ME2 
and 2OHE2 can reverse experimental PH and may well be useful in the treatment of the 
human disease.  
 
 
Figure 1. The potential effects of sex hormones and estrogen metabolites on pulmonary 
artery (PA) remodeling. In remodeled PA’s excess proliferation is observed in endothelial 
cells (blue), smooth muscle cells (orange) and fibroblasts (purple) eventually leading to 
reduced luminal area. Estrogen itself can increase vascular smooth muscle cell proliferation; 
however,  it has also been postulated to influence the Serotonin and Endothelin-1 pathways as 
well as reducing BMPRII signaling, all of which are recognized to be pro-proliferative 
mechanisms. The cytochrome P450 1B1 isoform (CYP1B) enzyme converts estrogen to 16α-
hydroxyestrone (16αOHE), a metabolite identified to be pro-proliferative by increasing 
oxidative stress responses. Other sex hormones such as testosterone, dehydroepiandrosterone 
DHEA and progesterone are known to be anti-proliferative and have been shown to reverse 
experimental PH. Some estrogen metabolites are also known to reverse experimental PH such 
as 2-hydroxyestradiol (2OHE2) and 2-methoxyestradiol (2ME2).  
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